• Теги
    • избранные теги
    • Компании194
      • Показать ещё
      Международные организации2
      • Показать ещё
      Страны / Регионы28
      • Показать ещё
      • Показать ещё
      • Показать ещё
12 июня, 22:54

Former EPA Employees Are So Worried About Trump's Plans, They Formed Their Own Alt-EPA

function onPlayerReadyVidible(e){'undefined'!=typeof HPTrack&&HPTrack.Vid.Vidible_track(e)}!function(e,i){if(e.vdb_Player){if('object'==typeof commercial_video){var a='',o='m.fwsitesection='+commercial_video.site_and_category;if(a+=o,commercial_video['package']){var c='&m.fwkeyvalues=sponsorship%3D'+commercial_video['package'];a+=c}e.setAttribute('vdb_params',a)}i(e.vdb_Player)}else{var t=arguments.callee;setTimeout(function(){t(e,i)},0)}}(document.getElementById('vidible_1'),onPlayerReadyVidible); This week, Environmental Protection Agency chief Scott Pruitt is slated to defend drastic cuts to his agency’s budget, including axing 25 percent of its staff and zeroing out climate change programs. In response, former EPA employees have formed a new bipartisan group called the Environmental Protection Network to help reporters, activists and policymakers penetrate an administration they accuse of waging an “ideologically driven” battle to cripple core functions of the agency. On Monday, the group hosted a call to brief reporters on what slashing 31 percent of the EPA’s budget would mean for the agency. The scientists, lawyers, economists and engineers in the network submitted detailed comments to the EPA cautioning officials against scrapping regulations just because industry deems them onerous. The organization, which does not yet have a website, also helped reporters phrase Freedom of Information Act requests to make them as specific as possible. “There are a variety of ways our experience and our unique institutional memory can help the work we can do,” Ruth Greenspan Bell, who worked for the EPA’s general counsel under President Bill Clinton, said on Monday’s call. The EPA did not respond to a request for comment. The Environmental Protection Network plans to help counter legislation passed in March by House Republicans to limit the types of scientific studies the EPA can use when drafting regulations. The bill comes as part of a larger push by the Republican-controlled White House and Congress to give industry more power over the rules that govern it. But don’t expect the EPN to join the ranks of the Sierra Club, Greenpeace and the Natural Resources Defense Council. “We don’t see ourselves as a green group,” said George Wyeth, who served as an EPA staff attorney for 27 years before leaving this January. “So we don’t see ourselves weighing in on narrow, specific issues. But we’ll take those one by one.” Pruitt, an avowed fossil fuel ally whose views on climate change clash with those of an overwhelming majority of scientists, has emerged as a powerful figure in the White House since President Donald Trump decided to withdraw the United States from the Paris climate agreement. Amid the waves made by Trump’s announcement, Pruitt rebuked his detractors as “climate exaggerators” and touted the United States’ success in lowering emissions. Yet he still wants to eliminate programs that helped the country get there. “Environmental protection is an ongoing process,” Greenspan Bell said. “This sort of suggestion that Pruitt is making, that the mission is accomplished, is unfathomable.” type=type=RelatedArticlesblockTitle=Related... + articlesList=593030dae4b07572bdbf9a33,5931b201e4b0c242ca23c825,593dee5be4b0c5a35ca0c160,58eeb500e4b0bb9638e13300,58adda3ce4b03d80af71a4eb -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

24 апреля, 18:40

Marathon man Matthew Rees: ‘It was fate. We were meant to cross the finish line together’

The London Marathon runner on how he got a memorable moment, if not a personal best time, when he helped fellow runner David Wyeth to finishIt has become the defining image of the 2017 London Marathon: Matthew Rees stopping 300 metres short of the finish line to help David Wyeth, a stranger on the verge of collapse, complete the race. “I was just about to sprint to the finish when I saw David,” Rees tells me. “His legs were completely jelly-like and he collapsed in front of me. So I decided to forget my race. He had come so far and after 26 miles of running I wanted him to make the finish.”Rees, who was running his third marathon as part of the Swansea Harriers club, was having a tough race himself. “Earlier on, some calf issues that I had been experiencing flared up and I was in a lot of pain,” he confesses. “I nearly dropped out but I decided I wanted to get to the finish line. When I saw David, he was clearly having the same thought. It felt like fate, that we were meant to cross together.” What did he say to him? “I was trying to motivate him and keep him coherent. I just kept on saying: ‘You will finish, I won’t leave your side, we’ll get to that finish line.’” Continue reading...

Выбор редакции
23 апреля, 17:05

London Marathon runner helps exhausted athlete finish race – video

This is the moment a London Marathon runner shows amazing sportsmanship and helps a fellow competitor over the finish line at the end of Sunday’s race. Swansea Harrier Matthew Rees sees David Wyeth of Chorlton Runners struggling to put one foot in front of the other with just 200m of the course remaining. Showing incredible selflessness, Rees slows down and supports Wyeth over the final metres to the finishKeitany and Wanjiru make it a memorable day for KenyaLondon Marathon footage courtesy of BBC Sport, watch more video clips here Continue reading...

08 февраля, 17:35

5 Best Alternative Mutual Funds for Skittish Investors

Alternative mutual funds are new product classes that hedge risks, provide unwavering returns and diversify portfolio.

27 января, 17:35

Pfizer (PFE) C. Difficile Vaccine Positive in Phase II Study

Pfizer Inc. (PFE) announced positive top-line results from a phase II study on its investigational vaccine candidate, PF-06425090, for the prevention of clostridium difficile infection.

Выбор редакции
12 декабря 2016, 11:04

Premium milk powder for pregnant women and new mothers

Irish Ambassador to China Paul Kavanagh speaks at the launch ceremony of illumcare, a premium maternal milk powder produced by Wyeth Nutrition, yesterday in Shanghai. The product, with ingredients exclusively imported from Ireland, is designed to help pregnant and lactating mothers build up and maintain healthy reserves of nutrients, thereby providing invaluable nutritional support during breastfeeding. It uses new food technology to make it easier for women to absorb iron with less gastrointestinal irritation.

01 декабря 2016, 13:31

Фонд Коэна заплатит последние $135 млн по делу об инсайде

Бывший хедж-фонд миллиардера Стивена Коэна SAC Capital Advisors LP, преобразованный сейчас в Point72 Asset Management LP, закроет вопрос, связанный со скандальным делом об инсайдерской торговле.

23 августа 2016, 19:10

Tuesday assorted links

1.  The economic value of book awards.  And “Perhaps even more impressive: the original English edition tops the current bestseller lists in both Germany and France.”  Link here. 2. 538 is hiring economics writers, and MRU is hiring. 3. Even low-wage Cambodia is automating. 4. Why don’t hotels give you toothpaste?  (The article could use […] The post Tuesday assorted links appeared first on Marginal REVOLUTION.

24 июня 2016, 03:37

Why Pfizer (PFE) is a Great Stock to Buy for the Long Run

Pfizer has a great dividend, and it generates an incredibly high level of sales, but here's why else this stock is worth keeping in your portfolio for the long haul.

11 марта 2016, 16:00

3 Top-Rated Market Neutral Funds to Dodge Volatility

Below we share with you three top-rated market neutral mutual funds. Each has earned a Zacks Mutual Fund Rank #1 (Strong Buy) as we expect the fund to outperform its peers in the future

Выбор редакции
03 марта 2016, 10:00

American beauty: Andrew Wyeth's painterly wonderland – in pictures

French photographer Joséphine Douet was so inspired by the late US painter that she followed in his tracks, shooting the barns and bark and bare beauty that inspired him in and around his hometown of Chadds Ford, Pennsylvania• The Secret Sits: Wyeth’s Wonderland is at the Museo Thyssen-Bornemisza, Madrid, until 19 June 2016. Continue reading...

25 февраля 2016, 16:15

5 Alternative Mutual Funds to Dodge Volatility in 2016

To weather market volatility and book in profits, alternative mutual funds are the best available choice.

Выбор редакции
16 февраля 2016, 14:58

Pfizer: Medicaid settlement tied to Wyeth and Protonix rebates between 2001 and 2006

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

24 декабря 2015, 18:40

SAC Capital to pay $10 million in investors' insider trading lawsuit

Billionaire Steven A. Cohen's former hedge fund SAC Capital Advisors LP has agreed to pay $10 million to resolve a lawsuit by shareholders of drugmaker Wyeth, who claimed they lost money because the fund engaged in insider trading in Wyeth's stock. The proposed settlement was disclosed in court papers filed on Wednesday in federal court in Manhattan and would resolve a class action launched following the arrest of a former SAC Capital portfolio manager, Mathew Martoma, for insider trading. Martoma was sentenced in 2014 to nine years in prison after being convicted of engaging in insider trading based on confidential results of a clinical trial of an Alzheimer's drug being developed by Elan Corp and Wyeth.

Выбор редакции
21 декабря 2015, 18:22

Supreme Court Ought To Re-examine Second-Guessing Of FDA-Approved Drug Labeling By State Tort Law

The U.S. Supreme Court’s 2009 decision in Wyeth v. Levine placed significant limits on the ability of brand-name drug manufacturers to defend against failure-to-warn state tort-law claims. Even though manufacturers invariably label their products precisely as the Food and Drug Administration (FDA) has mandated, Wyeth held that state courts could [...]

Выбор редакции
18 декабря 2015, 14:40

Biotech New Venture Formation: Reflecting On A Decade's Changing Dynamics

This year I celebrated my 10-year work anniversary with Atlas. Hard to believe how fast a decade flies by, and this milestone triggered some reflections on how times have changed in biotech and the early stage venture business. As we all know, the biopharma industry has changed a lot. Wyeth, Schering-Plough, [...]

04 декабря 2015, 22:34

Tax Dodging Just One Part of Pfizer's Corrupt Business Model

*This post orginally appeared on the blog of the Institute for New Economic Thinking. Oner Tulum and Matt Hopkins contributed to this post.There’s plenty that doesn’t add up about Pfizer’s claim that the low Irish tax rates it will pay by merging with Allergan are necessary if the company is to fund drug research to stay competitive. Consider that while the pharmaceutical giant was provisioning $2.2 billion for income taxes over the first nine months of this year, it was distributing five times as much – $11.4 billion – to its shareholders, $6.2 billion in stock buybacks and $5.2 billion in dividends. That was 159 percent of its profits over these three quarters.And for Pfizer such mind-numbing distributions to shareholders are nothing new. The company has been piling stock buybacks on top of dividends since 1985. From January 2001 through September 2015, Pfizer paid out $95.5 billion in buybacks and $87.1 billion in dividends, representing 117 percent of its net income. Meanwhile, it booked $37.1 billion in corporate income taxes to the IRS.Yet in a Wall Street Journal interview in October, to forestall the public criticism of corporate flight that was bound to come with the upcoming Pfizer-Allergan merger announcement, Pfizer CEO Ian C. Read moaned that its U.S. tax bill puts the company at a “tremendous disadvantage” in global competition. “We’re fighting,” Read said in the interview, “with one hand tied behind our back.” When one looks at Pfizer’s gargantuan distributions to shareholders, however, it is obvious that if Read can’t make use of both hands to secure innovation finance, it is not Uncle Sam who tied the knot.If Pfizer is cash-constrained, it is far more likely that it is the golden handcuffs of stock-based executive pay that are the source of the problem. In 2014, Read as CEO had total direct compensation of $22.6 million, of which 27 percent came from exercising stock options and 50 percent from the vesting of stock awards. The other four highest-paid executives named on Pfizer’s 2015 proxy statement averaged $8.0 million, with 24 percent from stock options and 41 percent from stock awards. Pfizer states that the company has a prime commitment to ” enhancing shareholder value,” a self-serving ideology for executives whose remuneration depends on the company’s stock-price performance. And stock buybacks provide a potent tool for manipulating a company’s stock price for the sake of enhancing executive stock-based pay.If we accept stock price as a measure of a company’s performance, then, compared with the S&P 500 Index, Pfizer has been successful over the years. Yet, as a company that is, as Read put in his Wall Street Journal interview, “doing what we need to do to ensure that we can continue to innovate,” Pfizer is a failure, and it is a failure for which American households as consumers, taxpayers, and workers have been paying a very high price. To see why Pfizer’s stock-price performance does not translate into superior economic performance, we need to delve into the inner working of the drug company’s business model. Let’s look at how Pfizer generates the profits that support its mega-distributions to shareholders and its stock-price performance.Over the past 15 years, Pfizer’s growth has been driven by three major acquisitions: Warner-Lambert in 2000, Pharmacia in 2003, and Wyeth in 2009, each one bringing with it a number of blockbuster drugs. The most lucrative by far has been Lipitor – already a huge blockbuster at Warner-Lambert when Pfizer acquired that company in 2000 – ringing up an annual average of $11.0 billion in sales from 2000 through 2011. But the Lipitor patent expired in 2010, and by 2014 its revenues had fallen to $2.1 billion, although it was still the fifth-best seller among Pfizer’s products.Pfizer is on the prowl for new blockbusters to fund its buyback habit. In 2014 AstraZeneca, the British-Swedish drug maker with strong sales in cancer drugs, rebuffed Pfizer’s takeover attempt. Now Pfizer has struck gold with Allergan, which owns the mega-seller Botox.Botox, known for its ability to erase wrinkles, was first approved by the FDA in 1989, 13 years before it was approved for cosmetic treatments. Over half of sales actually go to therapeutic uses such as spasticity, hyperhidrosis, and chronic migraine. New therapeutic indications have been found for Botox, resulting in new patent protection that will keep this drug valuable for a very long time.As has been the case with the takeovers of Warner-Lambert, Pharmacia, and Wyeth, Pfizer wants to get its greedy hands on blockbuster drugs that innovative companies have already developed and then, in the name of enhancing shareholder value, milk the acquisitions until the patents run dry. In merging with Allergan, Pfizer will gain from the corporate inversion, but compared with the profits to be generated by Allergan’s existing products, the Irish tax dodge is just icing on the Pfizer-Allergan wedding cake.From 2010 to 2014, Pfizer’s revenues fell from $67.8 billion to $49.6 billion, mainly because of the expiration of the patents on a number of the company’s blockbuster drugs. Over these four years, it slashed worldwide employment from 110,600 to 78,300. With Read as CEO, R&D spending has declined compared with the previous 15 years.Whatever its recorded R&D spending, however, Pfizer has long since lost the capability to generate its own drug products. Since 2001 the company has launched only four internally developed products, the last one in 2005. In 2010 sales of these four products totaled $3.7 billion, but, in part because of expiration of patents on two of the drugs, by 2014 these revenues had slumped to $1.3 billion.In 2014 the United States was Pfizer’s biggest national market, accounting for 38 percent of revenues. As Pfizer moves to Ireland, the U.S. market will remain critical to its profits not only because of its size but also because, unlike the governments of other major nations, Congress has chosen not to regulate drug prices. Going back decades, U.S. drug prices have been at least double those for the same products in other national markets. And over the past few years, Pfizer, along with many other U.S. pharmaceutical companies, has been aggressively jacking up drug prices even more, as a recent study shows.Yet whenever Congress has questioned the high prices, major U.S. drug companies say that they need the hefty profit margins to fund more R&D expenditures. For Pfizer, that argument may have held some water back in the ’80s. But for the past three decades Pfizer has been using its profits to enrich shareholders. U.S. taxpayers pay extortionate prices for indispensible pharmaceutical drugs so that companies like Pfizer, Merck, and J&J can do billions of dollars in buybacks every year to manipulate their companies’ stock prices. And top executives get paid many millions for this financial engineering.It gets worse. As the drug companies hold U.S. households hostage in our need to consume their products, taxpayers hand over massive amounts of hard-earned pay to support the drug companies’ R&D efforts. From 1938 through 2014, the National Institutes of Health (NIH) spent a total of $927 billion in 2014 dollars on life sciences research, and this year the NIH budget is over $30 billion— funded by taxpayers. Drug companies benefit from all sorts of other protections and subsidies, including those under the Orphan Drug Act of 1983. In Pfizer’s case, Lipitor, its most profitable drug to date, and Botox, its new shareholder-value enhancing therapy, both originated as orphan drugs.Since 2010, Pfizer’s annual sales have plunged by about $20 billion and its employment by more than 40,000 people. But Pfizer’s Read-era profit margins are at a record high for the company while Pfizer’s stock price has soared. If increasing its stock price is Pfizer’s raison d’être, then the allocation of more than 100 percent of profits to “enhancing shareholder value” through buybacks and dividends has worked – but at a huge cost to American innovation, employment, and income distribution.  -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

01 декабря 2015, 15:25

POLITICO Playbook, presented by JPMorgan Chase & Co. – QUIET RUBIO CAMPAIGN SHIFTS TO SPRINT -- 60 YEARS AGO TODAY, Rosa Parks kept her seat – PAUL RYAN’s beard – NYT’s new ’16 reporter -- B’DAY: Jen Psaki, Natalie Earnest, Karen Tumulty, Elizabeth Ralph

By Mike Allen (@mikeallen; mallen@politico.com) and Daniel Lippman (@dlippman; dlippman@politico.com) Good Tuesday morning, and welcome to December.SIXTY YEARS AGO today – on Dec. 1, 1955 -- Rosa Parks kept her seat, and changed the nation. See the first national story, on Dec. 5, 1955: “MONTGOMERY, Ala. (AP) -- A court test of segregated transportation loomed today following the arrest of a Negro who refused to move to the colored section of a city bus.” http://bit.ly/1RiZrfT The AP dispatch ran in the next day’s N.Y. Times – 10 grafs on p. 31, “BUSES BOYCOTTED OVER RACE ISSUE: Montgomery, Ala., Negroes Protest Woman's Arrest for Defying Segregation.” http://nyti.ms/1ls3PNg BREAKING – Reuters’ Jeff Mason in Paris: “Obama urged his Turkish counterpart … to reduce tensions with Russia, while stressing U.S. support for its NATO ally’s security. … ‘The United States supports Turkey’s right to defend itself and its air space ... We discussed how Turkey and Russia can work together to de-escalate tensions.’” http://reut.rs/1N1aSnp THE BIG PICTURE -- “He’ll always have Paris: It’s just not clear whether Obama’s trip will be remembered for climate change or terrorism,” by Politico’s Isaac Dovere in Paris: “Obama walked into meetings here … ahead of a year more likely than not to involve a conflict in Syria escalating far beyond what he’d wanted or planned. Instead of becoming the president who fulfilled his campaign promise of ending two wars, Obama’s looking like the president who didn’t quite end either, was drawn into a third, and could wind up in what some fear will become a fourth in Libya to prevent another ISIL haven from taking root.“‘Paris is a perfect metaphor for how world events can take over a president’s agenda,’ … said Rep. Adam Schiff (D-Calif.), the ranking Democrat on the House Intelligence Committee.” http://politi.co/1PY5E1o PIC DU JOUR: Speaker Ryan showed up at the Capitol yesterday with “what his office called his ‘hunting beard’ that he began growing Saturday at ‘deer camp.’” http://yhoo.it/1ls1a6g STATE OF THE UNION is Tue., Jan. 12. --“Congress actually set to pass bills — lots of them: Get ready for a legislative gusher to end the year,” by Jake Sherman: The House “is likely to move to overhaul a program that allows some foreign travelers to remain in the United States for three months without a visa. It’s just one of the legislative responses to the Syrian refugee crisis and terror attacks in Paris. … The House plans a vote this week on a rewrite of the Elementary and Secondary Education Act — a long-stalled rewrite of the 2001 No Child Left Behind law. … A five- or six-year highway bill could also come to a vote as soon as this week.” http://politi.co/1Nkxxdm RUBIO STRATEGERY – “Rubio pivots to his next stage: The Florida senator’s focus is finally shifting from political influencers to the voters themselves,” by Shane Goldmacher: “a more public-facing campaign. … He blitzed through New Hampshire on Monday, will campaign in South Carolina on Tuesday and then fly to Alabama, which votes on March 1 and where he will hold a rally, his first public event there this cycle. Rubio began to pick up the pace just before Thanksgiving, spending more time in Iowa just before the holiday – five straight days – than he did in the first six months of 2015 combined. …“The aggressive public travel schedule is being paired with a flood of new television ads. This week, his campaign blankets the Iowa and New Hampshire airwaves.” http://politi.co/1HCxptK ** A message from JPMorgan Chase & Co.: When Nishit Mehta drafted his small business plan 23 years ago, he recognized the risks were high. That's why he engaged top-level professors and business students and the University of Washington to be on his team. Learn more … http://bit.ly/1lK4vy1 ** HILLARY CLINTON to CHARLIE ROSE, for “Charlie Rose” and “CBS This Morning,” on why she has been slow to excite core Obama constituencies: “It’s a long time until these elections. … I see the energy and the enthusiasm growing at every one of my events. And I see a lot of young people at them. But campaigning is a day-to-day effort. You can't assume anything. I also wanna reach out to people who are alienated from politics, to give them a sense that I will care about them, too. I wanna be their president.“That’s why I rolled out a policy about what we should do in coal country. … Republicans are always beating up on the war on coal and accusing the president of that. We have to transition from coal, but we shouldn't do it at the expense of the people who've given their lives -- some of them at the cost of their lives -- to keep the lights on for more than a century. So let's talk about how we’re gonna help people in coal country. Let's try to find those areas where we can perhaps reach some accommodation.” --CLINTON, on putting American combat troops back into Syria or Iraq: “[A]t this point, I can not conceive of any circumstances where I would agree to do that, because I think the best way to defeat ISIS is, as I’ve said, from the air, which we lead; on the ground, which we enable ... train, equip; and in cyberspace … don’t forget, they are a formidable adversary online. …“[W]e don’t know yet how many Special Forces might be needed, how many trainer and surveillance and enablers might be needed. But in terms of thousands of combat troops like some on the Republican side are recommending, I think that should be a non-starter.” HAPPENING TODAY -- USA Today banner, “Pentagon mulls more special ops to Syria: Commandos are serving as advisers in ISIL fight,” by Tom Vanden Brook: “Adding more forces on the ground in Syria would represent a significant deepening of the U.S. commitment to the counter-ISIL effort, potentially requiring additional forces to support them. There are about 3,400 American forces in Iraq. The Pentagon's counter-ISIL strategy will be the focus of a hearing [at 10 a.m.] before the House Armed Services Committee; Defense Secretary Ash Carter is scheduled to testify.” http://usat.ly/1ThEdNW CLICKER: “The 15 must-read Clinton emails: The 7th release … included some doozies,” by Nick Gass: “Clinton's State Department kept a tight count of the secretary’s travels, … as evidenced by a June 2012 email from [Philippe] Reines to his boss and [Huma] Abedin. ‘With 7ish months left, plenty of time to run up the score on total countries. 110 is a reasonable goal. Here are the 94 countries left to choose from.’” http://politi.co/21rpYfA HILLARY RADIO AD, “My Story,” starts today on predominantly African American stations in South Carolina. She invokes her mother’s story of being abandoned by her parents, and her own story of working at the Children’s Defense Fund for South Carolinian Marian Wright Edelman after graduating law school. Listen here. http://bit.ly/1l4G7H8PLAYBOOK HIGHLIGHT REEL:BLAKE HOUNSHELL, “Murdoch unloads on Kerry, Obama, the left”: “‘Before delivering my modest message,’ Murdoch joked at the outset of his address accepting the Hudson Institute's Global Leadership Award [from Henry Kissinger in NYC last night], ‘I feel obliged to alert college students, progressive academics and all other deeply sensitive souls that these words may contain phrases and ideas that challenge your prejudices — in other words, I formally declare this room an “unsafe space.”’” http://politi.co/1l4MnihWHAT N.H. IS READING – Union Leader, bottom of p. 1, “Christie rides the momentum in NH … Governor welcomes fresh wave of endorsements,” by Dan Tuohy in Concord: “Reporters trailing Christie … were calling the endorsements something of a lifeline … Christie brushed that narrative aside. He said he’s running in ‘a wide open, competitive race,’ and ‘winning more and more converts every day.’” http://bit.ly/1IzeDP1SLAMMER FOR SHELLY – “Sheldon Silver convicted on all counts in corruption trial,” by Politico’s Colby Hamilton in Manhattan, and Albany Bureau Chief Jimmy Vielkind: “Silver — one of the most powerful men in Albany for two decades and … under five governors — was found guilty Monday of selling his office for legal fees … Silver, a Democrat … who resigned as speaker after being indicted earlier this year, [must] vacate his seat in the Assembly. He will be sentenced next year, and … could face up to 20 years in prison.” http://politi.co/1MTeM3D--TAB COVERS: N.Y. Post, “SHEL DONE!” http://bit.ly/1Xy78jU … Daily News, “CELLY SILVER!” http://nydn.us/vp5qdB … amNewYork, “CELL FOR SHEL.”NEW NYT POLITICAL REPORTER -- Carolyn Ryan, Senior Editor for Politics, emails the team:“Yamiche Alcindor [who started yesterday, and will be out on the trail a lot covering candidates, campaign news and social issues] comes to us from USA Today, where she has covered high-impact breaking news stories around the country, including Ferguson, the Boston marathon bombings, the George Zimmerman trial and the school shooting in Newtown … [S]he … writes and reports … shoots and edits video and has produced multi-media packages … at USA Today.“Yamiche is a graduate of Georgetown University and New York University, where she received her master's in broadcast news and documentary. Before joining USA Today, Yamiche worked at Newsday. She lives in Brooklyn.”JERRY SEIB “Capital Journal” column on WSJ A4, “Can Evangelicals Swing 2016 for Republicans?”: “Cruz appears to be making his move—two recent polls show him rising to second place in Iowa … Cruz argues, in essence, that an energized based of evangelical voters, 76% of whom are white, would make up for [under-enthusiasm that hurt Romney], and he is hitting that math hard to mobilize evangelicals. … [But] almost half of those in the evangelical population that Mr. Cruz cites aren’t Republicans.” http://on.wsj.com/1lrKpbfTOP TALKER – Coming in Friday’s N.Y. Times (Men’s Style, p. D20), “Does Celibacy Help Your Game?” by features reporter Steven Kurutz (online: “No Sex, Please. I Have a Game Tomorrow”): “Seattle Seahawks quarterback Russell Wilson has taken a public vow of celibacy [for Biblical reasons]. Will it help him on the field? Broadway Joe says no. … [I]f some players don’t keep themselves from having sex before big games, it remains a favorite tactic of coaches.” http://nyti.ms/1lrVSaH PLAYBOOK METRO SECTION – WashPost Style p. 2, “Say goodbye to ‘Christmas in Washington,’”by Helena Andrews-Dyer in “Reliable Source”: “After more than three decades and five administrations, ‘Christmas in Washington,’ the celebrity-packed holiday special attended by the first family, won’t be returning for its 34th holiday season. … After last year’s show, … TNT announced that it would no longer broadcast the Christmas special, ending a 15-year partnership with veteran producer George Stevens Jr. and his son, Michael. … [A] new network sponsor was never found.” http://wapo.st/1OBJij3BIRTHDAYS: Jen Psaki, White House communications director. Her mother, Eileen Medvey, and stepfather will be in town tonight, and she and Greg are going to go out to dinner for a rare date night. (hat tips: Greg, Vivi) ... Natalie Wyeth Earnest (h/t Josh, Walker) ... Karen Tumulty, the pride of San Antonio (hubby tip: Paul Richter and Joe Brettell) ... Shin Inouye ... Florida Gov. Rick Scott is 63 … POLITICO Magazine’s Elizabeth Ralph, the pride of Radnor, Pa. (h/t Olivia Petersen) ... Marylouise Oates (hubby tip: Bob Shrum) ... former CIA director Stansfield Turner is 92 … Kyle Lierman of the White House Office of Public Engagement ... Wayne Ting ... Raul Alvillar, DNC’s National Political Director ... Susan Stilts Collins ... Josh Kraushaar ... Natalie Ravitz, ... NPR’s Carrie Johnson ... Foreign Policy’s Yochi Dreazen ... Brett Lieberman ... David Seldin ... Donnie Fowler ... Jeri Henson Dies ...… Reggie Smith ... Ryan Bell ... Hayley D’Antuono is 24 (h/t Team Ratcliffe) ... Terri New, founder and president of Capital Strategies (h/t Jordan Markwith) ... Bruce Young ... Charlie Anderson (aka Uncanderson) ... Becky Weissman … Jake Kuitwaard … Terrie New … David Seldin … Randy Bauer … Dan McGuire … Jamie Domini … Jared Scott Small … Woody Allen is 80 … World Golf Hall of Famer Lee Trevino is 76 … television producer David Salzman is 72 … Bette Midler is 70 … Keith Thibodeaux (Little Ricky on “I Love Lucy”) is 65 … Charlene Tilton is 57 … Sarah Silverman is 45 … actor Jackson Nicoll is 12 (h/ts AP) ** A message from JPMorgan Chase & Co.: Small businesses created 63% of new jobs over the last 10 years (SBA). That’s why we support local entrepreneurs as they help create inclusive, community-based growth. Learn more about Irma’s in Houston, a pioneer in the Warehouse District, where they serve love and lemonade every day. http://bit.ly/1TeSVWw **SUBSCRIBE to the Playbook family: POLITICO Playbook: http://politi.co/1M75UbX ... New York Playbook: http://politi.co/1ON8bqW ... Florida Playbook: http://politi.co/1JDm23W ... New Jersey Playbook: http://politi.co/1HLKltF ... Massachusetts Playbook: http://politi.co/1Nhtq5v ... Illinois Playbook: http://politi.co/1N7u5sb ... California Playbook: http://politi.co/1N8zdJU and our friends atPOLITICO Brussels Playbook: http://politi.co/1FZeLcw

23 ноября 2015, 11:38

Pfizer плюс Allergan, или Как потратить $150 млрд

На фармацевтическом рынке назревает крупнейшая сделка M&A: по некоторым данным фармгигант Pfizer ведет переговоры по покупке другого игрока рынка Allergan за $150 млрд, что на 22% выше цены закрытия на прошлой неделе. О соглашении планируется объявить сегодня. Зачем Pfizer идет на столь масштабное поглощение?